15
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Myocarditis, paraparesia and ARDS associated to COVID-19 infection

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          An 18 year-old female patient with no medical history, no recent travel or exposure to animals, presented with fever and dyspnea to the Emergency Department on April 1st, 2020. She had been exposed to COVID-19 as her grandmother had tested positive two weeks earlier. As the symptoms were perfectly tolerated and there was no risk factor of severe infection, she was discharged without any laboratory testing. On Day 8 from the beginning of symptoms, as dyspnea worsened and she complained of chest pain, she was re-admitted to the Emergency Department. She had moderate fever of 38.3 °C. On clinical examination, the respiratory rate was 26/min, saturation 98% without oxygen, and pulmonary auscultation was normal. She presented with shock (low blood pressure at 70/42 mmHg, heart rate at 124/min, and elevated lactate at 2.9 mmol/mL). Cardiac auscultation was normal. Abdominal palpation showed non-specific pain. Lab tests showed: Troponin above 10,000 ng/ml, elevated NT-pro-BNP, high d-dimers and procalcitonin. She exhibited severe KDIGO 3 acute kidney injury (AKI) with anuria developing within the first 24 h. Baseline characteristics are outlined in Table 1 . A computed tomography performed on the day of admission showed moderate pulmonary lesions evocative of SARS-CoV2 infection (Fig 1 ). Table 1 Baseline characteristics of the patient on the day of admission to the ICU unit (Day 8 from the beginning of symptoms). Table 1 Variable Value Reference range Age 19 – Troponin (ng/mL) 10,652 < 12 NT-pro BNP (pg/mL) 2585 < 450 White cells count (per mm3) 22,880 3900–10,200 Hemoglobin (g/dL) 11.7 12–16 Hematocrit (%) 32.2 38.0 – 50.0 Platelet count (per mm3) 191,000 150,000 - 450,000 Sodium (mmol/liter) 123 135 – 145 Potassium (mmol/liter) 3.8 3.5 – 5 Chloride (mmol/liter) 84 95 – 105 Total proteins (g/liter) 65 58 – 80 Urea (mmol/liter) 13.6 2.5 – 7.6 Creatinine (µmol/liter) 272 65 – 110 Alanine aminotransferase (U/liter) 82 10 – 40 Aspartate aminotransferase (U/liter) 62 10 – 45 Procalcitonin (ng/ml) 67.6 < 0.1 D-dimers (ng/mL) 4235 < 450 Lactic acid (mmol/mL) 2.9 0.5 – 1.9 Fig. 1 Pulmonary CT-Scan evolution. Upper panels (Day 8) showing mild abnormalities compatible with SARS-CoV2 infections. Lower panels (Day 15) showing diffuse aveolo-interstitial edema compatible with ARDS COVID-19. Fig. 1 Fig. 2 Time course for clinical evolution from ICU admission to Day 17. Fig. 2 Echocardiography revealed severe dysfunction (ejection fraction 30%, aortic time velocity integral 9.5 cm for a cardiac index of 2.0 L/min/m2) with global hypokinesia. The electrocardiogram showed a sinusal rhythm without repolarization or conduction abnormalities (Supplementary Fig. 1). A perfusion of 750 mL of 0.9% saline serum did not improve hemodynamics. Norepinephrine was therefore introduced at a rate of 0.7 µg/kg/min, stabilizing the mean arterial pressure at 65 mmHg. Dobutamine was introduced up to 12.5 µg/kg/min. Control echocardiography showed a moderate improvement of cardiac function, with an aortic time velocity integral of 14 cm giving an estimated cardiac index of 3.5 L/min/m2 (Supplementary Videos & Supplementary Fig. 2). On Day 10 from the onset of symptoms, the patient displayed bilateral proximal paraparesia of the lower limbs, without any sphincter disorder, medullary level or deglutition difficulty. Tendon reflexes were abolished at the lower limbs. A brain and spinal MRI revealed no abnormality, whilst a lumbar puncture found no elevated proteins or cellular aberration. No microbial agent was found in the cerebrospinal fluid. The SARS-CoV2 RT-PCR in the cerebrospinal fluid was negative. Evolution was rapidly favorable for cardiogenic shock. On Day 12, the ejection fraction reached 50%, allowing a decrease of dobutamine dose (Fig. 2). AKI stabilized with a creatinine level of 230 µmol per liter, with slow resumption of diuresis. There was no associated hematuria or proteinuria. Repeated control of the electrocardiogram revealed no abnormality at any time. Upon admission to the intensive care unit, dyspnea and mild desaturation required oxygen at 2 liter per minute. Probabilistic antibiotherapy was introduced with cefotaxime, but was discontinued after three days when no microbial agent was found. Thereafter, on Day 12, fever rose to 41 °C, and despite the improvement of cardiogenic shock, respiratory function quickly deteriorated with worsening oxygen dependency and the necessity for endotracheal intubation. On the same day, the computed tomography found major images compatible with severe COVID-19 lesions (Fig. 1). There was no evidence of cardiac impairment in the worsening of the respiratory condition. The patient was treated with protective ventilation, neuromuscular blocking agents, prone ventilation and administration of nitric oxide. Intravenous corticotherapy by dexamethasone was initiated at Day 14 at a dose of 20 mg according to the protocol proposed by Villar et al. 1 Because respiratory function did not improve after two sessions of prone ventilation at Day 17, the patient was transferred for veno-venous extra-corporeal membrane oxygenation. In search of the cause of this multi-organ failure, a series of serologic tests (HIV, HBV, HBC, parvovirus B19, Borrelia burgdorferi, TPHA-VDRL, Chlamydiae, Mycoplasma) and PCR (including HSV, EBV, CMV, respiratory viruses panel, HHV8), were performed. All returned negative. Several blood cultures and bronchoalveolar fluid remained sterile. Rheumatoid factor and mumps serology turned positive for IgG and IgM at a low titer (1.9 UI/liter with a detection threshold of 1.5 UI/liter), compatible with non-specific immune response. Anti-nuclear antibodies and anti-neutrophil cytoplasmic antibodies were negative and, apart from moderate hyperferritinemia, no evidence was found of Adult Still disease. Several PCR samples for SARS-CoV2 were negative but were repeated as recommended 2 and with consideration to differing sensitivity depending on the sample site: three times in the nasopharynx, and once each in the serum, bronchoalveolar lavage fluid and urine. COVID-19 testing was finally positive on bronchoalveolar lavage fluid the day veno-venous extracorporeal membrane oxygenation was started. All investigations are summarized in Supplementary Table 1. We describe a complex case of multi-organ failure evolution with myocarditis usually associated with a very unfavorable prognosis, 3 and subsequently followed by respiratory failure. Pulmonary images quickly evolving from one CT-scan to the next and major hypoxemia upon endotracheal intubation were evocative of COVID-19, even though several PCR tests were initially negative. Interestingly, the onset of the disease did not include respiratory distress, which appeared at a later timepoint during evolution, after favorable evolution of myocarditis. To our knowledge, cases of non-coronary myocardial injury with ST segment elevation have been previously reported, 4 but it is the first described case of myocarditis subsequently followed by an acute distress respiratory syndrome secondary to SARS-CoV-2 infection. In this case, the implication of SARS-CoV-2 being responsible for acute inflammatory myocarditis seems more plausible than septic myocarditis, regarding elevated BNP and troponin, and echocardiography showing altered left ventricle ejection fraction and a low cardiac index. In addition, no other pathogen was found despite numerous blood cultures, serologies and PCR (Supplementary Table 1). Unfortunately, the course of clinical events did not allow us to perform electromyograms to confirm the suspected diagnosis of Guillain-Barré, as urgent transfer of the patient was necessary in order to implement veno-venous extracorporeal membrane oxygenation. A recent correspondence examined a series of five patients presenting with Guillain-Barré syndrome associated with COVID-19, 5 a clinical presentation compatible with our patient, even though the subsequent clinical evolution prevented us from performing any electrophysiological examination. In a report studying neurologic features during SARS-CoV2 infection, no RT-PCR assay was found positive in the cerebrospinal fluid. 6 As of April 20th, 2020, the patient remains hospitalized under veno-venous extracorporeal membrane oxygenation. This case suggests that there is a wide clinical spectrum of SARS-CoV2 infection, encompassing multi-organ failure and not necessarily always starting with acute respiratory syndrome. Declaration of Competing Interest None

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: found

          Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China

          In December 2019, novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) occurred in Wuhan, China. The number of cases has increased rapidly but information on the clinical characteristics of affected patients is limited.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Neurologic Features in Severe SARS-CoV-2 Infection

            To the Editor: We report the neurologic features in an observational series of 58 of 64 consecutive patients admitted to the hospital because of acute respiratory distress syndrome (ARDS) due to Covid-19. The patients received similar evaluations by intensivists in two intensive care units (ICUs) in Strasbourg, France, between March 3 and April 3, 2020. Six patients were excluded because of paralytic neuromuscular blockade when neurologic data were collected or because they had died without a neurologic examination having been performed. In all 58 patients, reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assays of nasopharyngeal samples were positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The median age of the patients was 63 years, and the median Simplified Acute Physiology Score II at the time of neurologic examination was 52 (interquartile range, 37 to 65, on a scale ranging from 0 to 163, with higher scores indicating greater severity of illness). Seven patients had had previous neurologic disorders, including transient ischemic attack, partial epilepsy, and mild cognitive impairment. The neurologic findings were recorded in 8 of the 58 patients (14%) on admission to the ICU (before treatment) and in 39 patients (67%) when sedation and a neuromuscular blocker were withheld. Agitation was present in 40 patients (69%) when neuromuscular blockade was discontinued (Table 1). A total of 26 of 40 patients were noted to have confusion according to the Confusion Assessment Method for the ICU; those patients could be evaluated when they were responsive (i.e., they had a score of −1 to 1 on the Richmond Agitation and Sedation Scale, on a scale of −5 [unresponsive] to +4 [combative]). Diffuse corticospinal tract signs with enhanced tendon reflexes, ankle clonus, and bilateral extensor plantar reflexes were present in 39 patients (67%). Of the patients who had been discharged at the time of this writing, 15 of 45 (33%) had had a dysexecutive syndrome consisting of inattention, disorientation, or poorly organized movements in response to command. Magnetic resonance imaging (MRI) of the brain was performed in 13 patients (Figs. S1 through S3 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Although these patients did not have focal signs that suggested stroke, they underwent MRI because of unexplained encephalopathic features. Enhancement in leptomeningeal spaces was noted in 8 patients, and bilateral frontotemporal hypoperfusion was noted in all 11 patients who underwent perfusion imaging. Two asymptomatic patients each had a small acute ischemic stroke with focal hyperintensity on diffusion-weighted imaging and an overlapping decreased apparent diffusion coefficient, and 1 patient had a subacute ischemic stroke with superimposed increased diffusion-weighted imaging and apparent diffusion coefficient signals. In the 8 patients who underwent electroencephalography, only nonspecific changes were detected; 1 of the 8 patients had diffuse bifrontal slowing consistent with encephalopathy. Examination of cerebrospinal fluid (CSF) samples obtained from 7 patients showed no cells; in 2 patients, oligoclonal bands were present with an identical electrophoretic pattern in serum, and protein and IgG levels were elevated in 1 patient. RT-PCR assays of the CSF samples were negative for SARS-CoV-2 in all 7 patients. In this consecutive series of patients, ARDS due to SARS-CoV-2 infection was associated with encephalopathy, prominent agitation and confusion, and corticospinal tract signs. Two of 13 patients who underwent brain MRI had single acute ischemic strokes. Data are lacking to determine which of these features were due to critical illness–related encephalopathy, cytokines, or the effect or withdrawal of medication, and which features were specific to SARS-CoV-2 infection.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Guillain–Barré Syndrome Associated with SARS-CoV-2

              To the Editor: From February 28 through March 21, 2020, in three hospitals in northern Italy, we examined five patients who had Guillain–Barré syndrome after the onset of coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). During that period, an estimated 1000 to 1200 patients with Covid-19 were admitted to these hospitals. Four of the patients in this series had a positive nasopharyngeal swab for SARS-CoV-2 at the onset of the neurologic syndrome, and one had a negative nasopharyngeal swab and negative bronchoalveolar lavage but subsequently had a positive serologic test for the virus. Detailed case reports are provided in the Supplementary Appendix, available with the full text of this letter at NEJM.org. The first symptoms of Guillain–Barré syndrome were lower-limb weakness and paresthesia in four patients and facial diplegia followed by ataxia and paresthesia in one patient (Table 1). Generalized, flaccid tetraparesis or tetraplegia evolved over a period of 36 hours to 4 days in four patients; three received mechanical ventilation. The interval between the onset of symptoms of Covid-19 and the first symptoms of Guillain–Barré syndrome ranged from 5 to 10 days (Table 1 and Fig. S1 in the Supplementary Appendix). None of the patients had dysautonomic features. On analysis of the cerebrospinal fluid (CSF), two patients had a normal protein level and all the patients had a white-cell count of less than 5 per cubic millimeter. Antiganglioside antibodies were absent in the three patients who were tested. In all the patients, a real-time polymerase-chain-reaction assay of the CSF was negative for SARS-CoV-2. Results of electrophysiological studies are shown in Table S1. Compound muscle action potential amplitudes were low but could be obtained; two patients had prolonged motor distal latencies. On electromyography, fibrillation potentials were present in three patients initially; in another patient, they were absent initially but were present at 12 days. The findings were generally consistent with an axonal variant of Guillain–Barré syndrome in three patients and with a demyelinating process in two patients. 1 Magnetic resonance imaging, performed with the administration of gadolinium, showed enhancement of the caudal nerve roots in two patients, enhancement of the facial nerve in one patient, and no signal changes in nerves in two patients. Additional laboratory findings are shown in Table S2. All the patients were treated with intravenous immune globulin (IVIG); two received a second course of IVIG and one started plasma exchange. At 4 weeks after treatment, two patients remained in the intensive care unit and were receiving mechanical ventilation, two were undergoing physical therapy because of flaccid paraplegia and had minimal upper-limb movement, and one had been discharged and was able to walk independently. The interval of 5 to 10 days between the onset of viral illness and the first symptoms of Guillain–Barré syndrome is similar to the interval seen with Guillain–Barré syndrome that occurs during or after other infections. 2 Although many infectious agents have been associated with Guillain–Barré syndrome, there may be a propensity for preceding infection with Campylobacter jejuni, Epstein–Barr virus, cytomegalovirus, and Zika virus. There have been reports of an association between Guillain–Barré syndrome and coronavirus infections. 3,4 On the basis of this observational series involving five patients, it is not possible to determine whether severe deficits and axonal involvement are typical features of Covid-19–associated Guillain–Barré syndrome. We could not determine the effect of reduced vital capacity due to neuromuscular failure from Guillain–Barré syndrome in these patients, but such an effect might be considered if findings on chest imaging are not commensurate with the severity of respiratory insufficiency. Guillain–Barré syndrome with Covid-19 should be distinguished from critical illness neuropathy and myopathy, which tend to appear later in the course of critical illness than Guillain–Barré syndrome.
                Bookmark

                Author and article information

                Journal
                Heart Lung
                Heart Lung
                Heart & Lung
                Elsevier Inc.
                0147-9563
                1527-3288
                19 October 2020
                19 October 2020
                Affiliations
                [a ]Intensive Care Unit, Poissy Saint Germain Hospital, 9-10 rue du champ Gaillard, Poissy 78300, France
                [b ]Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
                [c ]INSERM U-1018, CESP, Team “Epidemiologie Clinique”, UVSQ, Villejuif, France
                Author notes
                [* ]Corresponding author.
                Article
                S0147-9563(20)30401-5
                10.1016/j.hrtlng.2020.10.008
                7571901
                f1eb3220-5866-489c-bc2f-316546a46541
                © 2020 Elsevier Inc. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 17 August 2020
                : 25 September 2020
                : 16 October 2020
                Categories
                Article

                Comments

                Comment on this article